Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of advanced EGFR‐mutated non‐small cell lung cancer (NSCLC) with prolonged overall survival (OS) compared with platinum‐based doublet chemotherapy in several phase III trials [1, 2, 3, 4, 5]. The gene discussed is EGFR; the disease is lung cancer.